Treatment of Palmar Pustulosis
The combination of oral PUVA with oral retinoids (acitretin) is the most strongly recommended treatment for palmoplantar pustulosis, with 100% clearance rates in controlled trials, though newer biologics like guselkumab and bimekizumab show promise for refractory cases. 1
First-Line Treatment Algorithm
Oral PUVA + Acitretin (Strongest Evidence)
- Start with combination therapy immediately rather than monotherapy if there are no contraindications 1
- Evidence shows 100% clearance (8/8 patients) with oral PUVA-etretinate combination vs. only 44% (4/9) with PUVA alone 1
- Another trial demonstrated 61% clearance with combination vs. 21% with PUVA monotherapy 1
- This combination reduces the number of PUVA treatments needed, thereby decreasing long-term skin cancer risk 2
Dosing specifics:
- Acitretin: 25-50 mg daily (start at 25 mg and titrate based on tolerability) 3, 2
- Oral PUVA: 2-3 times weekly for several months 2
- Monitor lipids (manage elevated triglycerides with fibrates, cholesterol with statins) 2
Important Contraindications to Consider:
- Acitretin: Pregnancy (teratogenic with 3-year washout period for women of childbearing potential) 3
- PUVA: Pregnancy, history of multiple skin cancers, photosensitivity disorders 1
Second-Line Options (When First-Line Fails or Contraindicated)
Oral PUVA Monotherapy
- Use if retinoids are contraindicated 1
- 100% improvement rate vs. 59% with no treatment in controlled studies 1
- Clearance rates: 21-55% as monotherapy 1
- Critical caveat: Topical PUVA is NOT effective for palmoplantar pustulosis (0-10% clearance rates) 1
Acitretin Monotherapy
- Effective for pustular variants with rapid response possible 3
- 84% improvement in pustular psoriasis studies 3
- Dose: 10-50 mg daily (balance efficacy with tolerability) 3
- Can combine with narrowband UVB if PUVA unavailable 3
Third-Line: Biologics for Refractory Disease
Guselkumab (IL-23 inhibitor)
- Highest probability of efficacy among biologics based on network meta-analysis 4
- Guselkumab 100 mg showed mean PPPASI reduction of -8.00 (95% CI: 4.88-11.11) 4
- Consider when conventional therapies fail 4, 5
Bimekizumab (IL-17A/F inhibitor)
- Emerging as highly effective: 17/21 patients (81%) achieved complete clearance in 1-4 months 6
- Particularly valuable for refractory cases that failed multiple systemic treatments 6, 7
- Targets both IL-17A and IL-17F pathways 6
- Main adverse event: candidiasis (19% of patients, easily managed with oral antifungals) 6
JAK Inhibitors (Tofacitinib)
- Rescue therapy after apremilast failure: 88.9% achieved PPPASI50 by 12 weeks 8
- Dose: 5 mg twice daily 8
- Good tolerability profile in case series 8
Treatments to AVOID
TNF-α Inhibitors
- Paradoxically can INDUCE palmoplantar pustulosis in patients without prior psoriasis 2, 9
- Small pilot study showed no benefit of etanercept over placebo 9
- Should be avoided in palmoplantar pustulosis specifically 9
Topical PUVA
- Multiple RCTs show no significant benefit over placebo 1
- Clearance rates only 0-10% 1
- Do not waste time with this modality 1
Alternative Systemic Options
When phototherapy and retinoids are unsuitable:
- Methotrexate: Effective but monitor for hepatotoxicity and bone marrow toxicity 2
- Cyclosporine: Effective but nephrotoxicity concerns 2
- Both justified given the disproportionate impact on quality of life despite small body surface area involved 2
Critical Clinical Pearls
Long-term cancer risk management:
- PUVA increases squamous cell carcinoma risk with cumulative exposure 2
- Minimize total number of PUVA treatments by using combination therapy 1, 2
- Cutaneous malignancy on palms/soles after topical PUVA is very rare, but sun-exposed skin remains at risk 2
Quality of life consideration:
- Palmoplantar disease causes disability out of proportion to body surface area affected 2
- Systemic therapy is justified even for localized disease 2
- Patients experience limitations in basic functions (walking, buttoning clothing) and significant pain 2
Monitoring requirements: